Related references
Note: Only part of the references are listed.Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders
N. Singewald et al.
PHARMACOLOGY & THERAPEUTICS (2015)
FAAH genetic variation enhances fronto-amygdala function in mouse and human
Iva Dincheva et al.
NATURE COMMUNICATIONS (2015)
Amygdala-Hippocampal Volume and the Phenotypic Heterogeneity of Posttraumatic Stress Disorder: A Cross-Sectional Study
Robert H. Pietrzak et al.
JAMA PSYCHIATRY (2015)
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Le-Ben Wan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
A. McGirr et al.
PSYCHOLOGICAL MEDICINE (2015)
Peripheral and central mechanisms of stress resilience
Madeline L. Pfau et al.
NEUROBIOLOGY OF STRESS (2015)
The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder
Amy F. T. Arnsten et al.
NEUROBIOLOGY OF STRESS (2015)
The Dopamine β-Hydroxylase Inhibitor, Nepicastat, Reduces Different Alcohol-Related Behaviors in Rats
Giancarlo Colombo et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2014)
Neuropeptide Y Receptor Gene Expression in the Primate Amygdala Predicts Anxious Temperament and Brain Metabolism
Patrick H. Roseboom et al.
BIOLOGICAL PSYCHIATRY (2014)
Conditional Inactivation of Neuropeptide Y Y1 Receptors Unravels the Role of Y1 and Y5 Receptors Coexpressing Neurons in Anxiety
Angela Longo et al.
BIOLOGICAL PSYCHIATRY (2014)
The endocannabinoid system modulates stress, emotionality, and inflammation
Molly S. Crowe et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders
Olena Bukalo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder
Pablo Roitman et al.
CLINICAL DRUG INVESTIGATION (2014)
FROM THE NEUROBIOLOGY OF EXTINCTION TO IMPROVED CLINICAL TREATMENTS
Filomene G. Morrison et al.
DEPRESSION AND ANXIETY (2014)
Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents
Daniel F. Connor et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
Atul R. Mahableshwarkar et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2014)
Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
Michael E. Thase et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Agomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Dan J. Stein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Effect of Pregabalin Augmentation in Treatment of Patients with Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial
Mehdi Baniasadi et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2014)
D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial
JoAnn Difede et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder
Renu Sah et al.
PSYCHONEUROENDOCRINOLOGY (2014)
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial
Boadie W. Dunlop et al.
TRIALS (2014)
The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology
Bruce N. Cuthbert
WORLD PSYCHIATRY (2014)
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder A Randomized Clinical Trial
Adriana Feder et al.
JAMA PSYCHIATRY (2014)
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial
James W. Murrough et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Treatment of anxiety disorders in epilepsy: An evidence-based approach
Marco Mula
EPILEPSIA (2013)
The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
Lee A. Dawson
EXPERT OPINION ON DRUG DISCOVERY (2013)
Glutamate-based anxiolytic ligands in clinical trials
Joanna M. Wieronska et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression
Dan J. Stein et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2013)
An Open-Label Study of Guanfacine Extended Release for Traumatic Stress Related Symptoms in Children and Adolescents
Daniel F. Connor et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2013)
Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study
A. Neumeister et al.
MOLECULAR PSYCHIATRY (2013)
50 years of hurdles and hope in anxiolytic drug discovery
Guy Griebel et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Carolyn I. Rodriguez et al.
NEUROPSYCHOPHARMACOLOGY (2013)
SINGLE INTRANASAL NEUROPEPTIDE Y INFUSION ATTENUATES DEVELOPMENT OF PTSD-LIKE SYMPTOMS TO TRAUMATIC STRESS IN RATS
L. I. Serova et al.
NEUROSCIENCE (2013)
Endocannabinoid system and mood disorders: Priming a target for new therapies
Vincenzo Micale et al.
PHARMACOLOGY & THERAPEUTICS (2013)
The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons
Pim Cuijpers et al.
WORLD PSYCHIATRY (2013)
Assessing the fit of the Dysphoric Arousal model across two nationally representative epidemiological surveys: The Australian NSMHWB and the United States NESARC
Cherie Armour et al.
JOURNAL OF ANXIETY DISORDERS (2013)
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Michael H. Bloch et al.
BIOLOGICAL PSYCHIATRY (2012)
EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)
Mehdi Sayyah et al.
DEPRESSION AND ANXIETY (2012)
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
Anthony J. Rothschild et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
Leszek Bidzan et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Synergistic mechanisms involved in the antidepressant effects of agomelatine
Daniela Tardito et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
David S. Baldwin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study
Charles Merideth et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
Agomelatine Prevents Relapse in Generalized Anxiety Disorder: A 6-Month Randomized, Double-Blind, Placebo-Controlled Discontinuation Study
Dan J. Stein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Guy Griebel et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Biological studies of post-traumatic stress disorder
Roger K. Pitman et al.
NATURE REVIEWS NEUROSCIENCE (2012)
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder
Amy L. Mahan et al.
TRENDS IN NEUROSCIENCES (2012)
A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial
Sanjay J. Mathew et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2011)
Central functions of neuropeptide Y in mood and anxiety disorders
Gang Wu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder
Panagiotis Oulis et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2011)
Evidence-based pharmacological treatment of generalized anxiety disorder
David S. Baldwin et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related PTSD A Randomized Trial
John H. Krystal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder
Arifulla Khan et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder A Double-Blind, Placebo-Controlled Study
Maria Rosaria A. Muscatello et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
Benny Bang-Andersen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects
Eva M. Marco et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2011)
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
David Baldwin et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Michael W. Otto et al.
BIOLOGICAL PSYCHIATRY (2010)
Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties
John E. Tellew et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
John H. Krystal et al.
CNS DRUGS (2010)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR AND PLACEBO-CONTROLLED TRIAL OF A CORTICOTROPIN-RELEASING FACTOR RECEPTOR-1 ANTAGONIST IN GENERALIZED ANXIETY DISORDER
Vladimir Coric et al.
DEPRESSION AND ANXIETY (2010)
THE RELATIONSHIP BETWEEN ANXIETY DISORDERS AND SUICIDE ATTEMPTS: FINDINGS FROM THE NATIONAL EPIDEMIOLOGIC SURVEY ON ALCOHOL AND RELATED CONDITIONS
Josh Nepon et al.
DEPRESSION AND ANXIETY (2010)
Therapeutic potential of neuropeptide Y (NPY) receptor ligands
Shaun P. Brothers et al.
EMBO MOLECULAR MEDICINE (2010)
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder
Johannes Tauscher et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care
Elisa Martin-Merino et al.
FAMILY PRACTICE (2010)
The Burden of Anxiety Disorders on the Family
Rhandi Senaratne et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2010)
Low Cerebrospinal Fluid Neuropeptide Y Concentrations in Posttraumatic Stress Disorder
Renu Sah et al.
BIOLOGICAL PSYCHIATRY (2009)
SEVERITY OF ANXIETY AND WORK-RELATED OUTCOMES OF PATIENTS WITH ANXIETY DISORDERS
Steven R. Erickson et al.
DEPRESSION AND ANXIETY (2009)
Cannabis and anxiety: a critical review of the evidence
Jose Alexandre Crippa et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2009)
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial
Siegfried Kasper et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Functional Interactions between Endocannabinoid and CCK Neurotransmitter Systems May Be Critical for Extinction Learning
Jasmeer P. Chhatwal et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological, and Behavioral Characterization
Alain Gobert et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
Amelie Soumier et al.
NEUROPSYCHOPHARMACOLOGY (2009)
The psychiatric side-effects of rimonabant
Fabricio A. Moreira et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2009)
Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder
Elizabeth A. Hoge et al.
CNS SPECTRUMS (2008)
Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder
J. R. Strawn et al.
DEPRESSION AND ANXIETY (2008)
Central CRH system in depression and anxiety -: Evidence from clinical studies with CRH1 receptor antagonists
Florian Holsboer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study
Dan J. Stein et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Aripiprazole in the treatment of posttraumatic stress disorder. An open-label trial
Marcelo Feijo Mello et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2008)
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder
Eduardo Dunayevich et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders
Daniel M. Tassone et al.
CLINICAL THERAPEUTICS (2007)
No improvement of posttraumatic stress disorder symptoms with guanfacine treatment
Thomas C. Neylan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
The role of substance P in stress and anxiety responses
K. Ebner et al.
AMINO ACIDS (2006)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Carlos A. Zarate et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Plasma neuropeptide y concentrations in combat exposed veterans: Relationship to trauma exposure, recovery from PTSD, and coping
R Yehuda et al.
BIOLOGICAL PSYCHIATRY (2006)
Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression
TD Geracioti et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740
V Bergink et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study
O Brawman-Mintzer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Pregabalin for treatment of generalized anxiety disorder - A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam
K Rickels et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain
J Hietala et al.
MOLECULAR IMAGING AND BIOLOGY (2005)
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication
RC Kessler et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors
DE Adson et al.
JOURNAL OF AFFECTIVE DISORDERS (2005)
Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor
DR Gehlert et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats
H Wang et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2005)
Substance P receptor antagonists in psychiatry - Rationale for development and therapeutic potential
I Herpfer et al.
CNS DRUGS (2005)
Disability, employment and work performance among people with ICD-10 anxiety disorders
G Waghorn et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2005)
The NPY system in stress, anxiety and depression
M Heilig
NEUROPEPTIDES (2004)
Cognitive enhancers as adjuncts to psychotherapy - Use of D-cycloserine in phobic individuals to facilitate extinction of fear
KJ Ressler et al.
ARCHIVES OF GENERAL PSYCHIATRY (2004)
Corticotropin-releasing factor in posttraurnatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects
FJ Sautter et al.
BIOLOGICAL PSYCHIATRY (2003)
Pregabalin in generalized anxiety disorder: A placebo-controlled trial
AC Pande et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Prevalence of sexual dysfunction among newer antidepressants
AH Clayton et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder
MW Otto et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
CSF norepinephrine concentrations in posttraumatic stress disorder
TD Geracioti et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Early coadministration of clonazepam with sertraline for panic disorder
AW Goddard et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD
AM Rasmusson et al.
BIOLOGICAL PSYCHIATRY (2000)
Share Paper
